Healthcare Market Research Reports & Industry Analysis

Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.

Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.

The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.

Publications found: 69,579

Sort by:

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) Drugs in Development by Therapy Are...

May 2022 70 pages

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Drugs in Development by Therapy Areas and Indicati...

May 2022 124 pages

Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2) Drugs in Development by Ther...

May 2022 43 pages

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stag...

May 2022 112 pages

Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56...

May 2022 38 pages

Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or PTPN11 or EC 3.1.3.48) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Tyrosine Protein Phosphatase Non Receptor Type 11 (Protein Tyrosine Phosphatase 1D or Protein Tyrosine Phosphatase 2C or SHP2 or SHPTP2 or SH PTP3 or PTPN11 or EC 3.1.3.48) Drugs in Development by The...

May 2022 57 pages

Ubiquitin Carboxyl Terminal Hydrolase 14 (Deubiquitinating Enzyme 14 or Ubiquitin Thioesterase 14 or Ubiquitin Specific Processing Protease 14 or USP14 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 14 (Deubiquitinating Enzyme 14 or Ubiquitin Thioesterase 14 or Ubiquitin Specific Processing Protease 14 or USP14 or EC 3.4.19.12) Drugs in Development by Therapy...

May 2022 35 pages

Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub Specific Protease 30 or USP30 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 30 (Deubiquitinating Enzyme 30 or Ubiquitin Thioesterase 30 or Ubiquitin Specific Processing Protease 30 or Ub Specific Protease 30 or USP30 or EC 3.4.19.12) Drug...

May 2022 35 pages

Ubiquitin Carboxyl Terminal Hydrolase 7 (Deubiquitinating Enzyme 7 or Ubiquitin Thioesterase 7 or Herpesvirus Associated Ubiquitin Specific Protease or Ubiquitin Specific Processing Protease 7 or USP7 or EC 3.4.19.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Carboxyl Terminal Hydrolase 7 (Deubiquitinating Enzyme 7 or Ubiquitin Thioesterase 7 or Herpesvirus Associated Ubiquitin Specific Protease or Ubiquitin Specific Processing Protease 7 or USP7...

May 2022 38 pages

Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, R...

May 2022 35 pages

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or EC 2.3.2.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Ubiquitin Protein Ligase E3A (Renal Carcinoma Antigen NY REN 54 or Human Papillomavirus E6 Associated Protein or Oncogenic Protein Associated Protein E6 AP or E6AP Ubiquitin Protein Ligase or UBE3A or...

May 2022 45 pages

UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108) Drugs in Development by Therapy Areas and Indication...

May 2022 39 pages

V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation (Platelet Receptor Gi24 or Stress Induced Secreted Protein 1 or PD1H or V Set Domain Containing Immunoregulatory Receptor or B7H5 or VISTA or VSIR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation (Platelet Receptor Gi24 or Stress Induced Secreted Protein 1 or PD1H or V Set Domain Containing Immunoregulatory Receptor or B7H...

May 2022 42 pages

Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or F...

May 2022 77 pages

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) Drugs in Develo...

May 2022 138 pages

Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indicatio...

May 2022 71 pages

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) Drugs in Development by Ther...

May 2022 36 pages

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasopressin V1b Receptor (AVPR V1b or AVPR V3 or Antidiuretic Hormone Receptor 1b or Vasopressin V3 Receptor or AVPR3 or AVPR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA...

May 2022 38 pages

Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA,...

May 2022 45 pages

Voltage Dependent Anion Selective Channel Protein 1 (Outer Mitochondrial Membrane Protein Porin 1 or Plasmalemmal Porin or Porin 31HL or VDAC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Voltage Dependent Anion Selective Channel Protein 1 (Outer Mitochondrial Membrane Protein Porin 1 or Plasmalemmal Porin or Porin 31HL or VDAC1) Drugs in Development by Therapy Areas and Indications, S...

May 2022 36 pages

Voltage Dependent N Type Calcium Channel Subunit Alpha 1B (Voltage Gated Calcium Channel Subunit Alpha Cav2.2 or Brain Calcium Channel III or CACNA1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Voltage Dependent N Type Calcium Channel Subunit Alpha 1B (Voltage Gated Calcium Channel Subunit Alpha Cav2.2 or Brain Calcium Channel III or CACNA1B) Drugs in Development by Therapy Areas and Indicat...

May 2022 36 pages

Werner Syndrome ATP Dependent Helicase (DNA Helicase RecQ Like Type 3 or Exonuclease WRN or RecQ Protein Like 2 or WRN or EC 3.6.4.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Werner Syndrome ATP Dependent Helicase (DNA Helicase RecQ Like Type 3 or Exonuclease WRN or RecQ Protein Like 2 or WRN or EC 3.6.4.12) Drugs in Development by Therapy Areas and Indications, Stages, Mo...

May 2022 38 pages

16S Ribosomal RNA (16S rRNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

16S Ribosomal RNA (16S rRNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 16S Ribosomal RNA (16S rRNA) Drugs in Development by Therapy...

May 2022 71 pages

23S Ribosomal RNA (23S rRNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

23S Ribosomal RNA (23S rRNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 23S Ribosomal RNA (23S rRNA) Drugs in Development by Therapy...

May 2022 61 pages

30S Ribosomal Subunit (30S RNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

30S Ribosomal Subunit (30S RNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 30S Ribosomal Subunit (30S RNA) Drugs in Development by T...

May 2022 44 pages

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 3C Like Proteinase (3CL-PRO or 3CLp or...

May 2022 79 pages

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydr...

May 2022 119 pages

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type a...

May 2022 53 pages

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 54 pages

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydroxytryptamine Receptor 2 (5...

May 2022 200 pages

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydroxytrypt...

May 2022 169 pages

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and...

May 2022 58 pages

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydroxytryptamine Recep...

May 2022 56 pages

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydroxytryptamin...

May 2022 43 pages

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 3,500.00

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 5-Hydroxytrypta...

May 2022 303 pages

50S Ribosomal Subunit (50S RNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

50S Ribosomal Subunit (50S RNA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 50S Ribosomal Subunit (50S RNA) Drugs in Development by T...

May 2022 37 pages

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY 70 kDa Ribosomal Protein S6 Ki...

May 2022 37 pages

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Acetyl...

May 2022 36 pages

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Acetyl CoA Ca...

May 2022 43 pages

Achromatopsia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Achromatopsia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Achromatopsia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players prov...

May 2022 36 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Di...

May 2022 37 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Di...

May 2022 38 pages

Acquired (Autoimmune) Hemolytic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Acquired (Autoimmune) Hemolytic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acquired (Autoimmune) Hemolytic Anemia Drugs in Development by Stages, Ta...

May 2022 210 pages

Acral Lentiginous Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acral Lentiginous Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acral Lentiginous Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule...

May 2022 35 pages

Acute Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Bronchitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Player...

May 2022 35 pages

Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type...

May 2022 54 pages

Acute Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Heart Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 51 pages

Acute Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Inflammation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Pl...

May 2022 45 pages

Acute Ischemic Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Ischemic Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Ischemic Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and...

May 2022 114 pages

Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key...

May 2022 46 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

33% OFF on “TCR-Based Antibody a...

Discount Offer from GMD Research

280

Special Offer from MP Advisors

Special Offer on Therapy Class R...